Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Clifford Mault

Internal Medicine Sylva, NC Doctor of Osteopathy

NPI 1902870736 CMS profile 86748

12 Grindstaff Cove Rd, Sylva, NC 28779

Open in the dashboard

General payments

$12,453

634 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clifford Mault of Sylva, NC is reported in the CMS Open Payments database as having received $12,453 across 634 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,062 89
2024 General $1,729 82
2023 General $1,851 91
2022 General $1,592 80
2021 General $2,611 129
2020 General $1,526 106
2019 General $1,082 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clifford Mault
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Clifford Mault were reported at $2,062. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Clifford Mault Internal Medicine median Middle half National median
2019 $1,082 $159 $48–$570 $163
2020 $1,526 $119 $33–$402 $114
2021 $2,611 $135 $37–$521 $132
2022 $1,592 $141 $42–$496 $149
2023 $1,851 $149 $45–$519 $160
2024 $1,729 $154 $47–$537 $164
2025 $2,062 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,645 83 payments
  2. Novo Nordisk Inc $1,395 76 payments
  3. Pfizer Inc. $1,383 75 payments
  4. AstraZeneca Pharmaceuticals LP $1,268 55 payments
  5. Amgen Inc. $995 53 payments
  6. Lilly USA, LLC $915 49 payments
  7. Janssen Pharmaceuticals, Inc $630 26 payments
  8. Allergan Inc. $473 29 payments
  9. Merck Sharp & Dohme Corporation $440 26 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $370 16 payments
  11. Other $2,939 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,392 631 payments
  2. Education $61 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $935 43 payments
  2. Ozempic $899 58 payments
  3. RYBELSUS $659 45 payments
  4. ELIQUIS $635 33 payments
  5. XARELTO $630 26 payments
  6. BREZTRI $561 18 payments
  7. Otezla $532 31 payments
  8. Repatha $485 32 payments
  9. BELSOMRA $429 25 payments
  10. VRAYLAR Neuroscience $398 25 payments
  11. Other $10,916 585 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 166 drugs

Part D claims

7,946

Median for Internal Medicine: 777

Drug cost

$618,830

Median for Internal Medicine: $73,373

Branded share of claims

25.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 54 $68,748
Eliquis Apixaban Brand 74 $56,507
Mounjaro Tirzepatide Brand 51 $53,322
Jardiance Empagliflozin Brand 41 $36,981
Xarelto Rivaroxaban Brand 46 $33,874
Xtampza Er Oxycodone Myristate Brand 25 $28,594
Topamax Topiramate Brand 11 $21,351
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $21,255
Linzess Linaclotide Brand 30 $20,427
Repatha Sureclick Evolocumab Brand 19 $18,588

The 10 drugs with the highest cost, of 166 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$97,465

Of which drugs: $3,557

Medicare patients

200

Average age 71

Services billed

6,018

101 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 38%
Diabetes 29%
Ischemic heart disease 21%
Depression 20%
Chronic kidney disease 17%
COPD 15%
Heart failure 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 14 107 $550
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 11 11 $241
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 353 $180
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 156 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$167 — —
FANAPT
$121 — —
Otezla
$116 — —
MOUNJARO
$100 51 —
REXULTI
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

634 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record